JP2017505777A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505777A5
JP2017505777A5 JP2016549300A JP2016549300A JP2017505777A5 JP 2017505777 A5 JP2017505777 A5 JP 2017505777A5 JP 2016549300 A JP2016549300 A JP 2016549300A JP 2016549300 A JP2016549300 A JP 2016549300A JP 2017505777 A5 JP2017505777 A5 JP 2017505777A5
Authority
JP
Japan
Prior art keywords
sdc
trap
daltons
moiety
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016549300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017505777A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/013440 external-priority patent/WO2015116774A1/en
Publication of JP2017505777A publication Critical patent/JP2017505777A/ja
Publication of JP2017505777A5 publication Critical patent/JP2017505777A5/ja
Pending legal-status Critical Current

Links

JP2016549300A 2014-01-29 2015-01-29 標的化治療薬 Pending JP2017505777A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461933224P 2014-01-29 2014-01-29
US61/933,224 2014-01-29
PCT/US2015/013440 WO2015116774A1 (en) 2014-01-29 2015-01-29 Targeted therapeutics

Publications (2)

Publication Number Publication Date
JP2017505777A JP2017505777A (ja) 2017-02-23
JP2017505777A5 true JP2017505777A5 (https=) 2018-02-08

Family

ID=53757707

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016549300A Pending JP2017505777A (ja) 2014-01-29 2015-01-29 標的化治療薬

Country Status (4)

Country Link
US (1) US10117944B2 (https=)
EP (1) EP3099332A4 (https=)
JP (1) JP2017505777A (https=)
WO (1) WO2015116774A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015066053A2 (en) * 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
AU2015224576A1 (en) 2014-03-03 2016-09-22 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
PT109941B (pt) * 2017-03-02 2021-02-09 Hovione Farmaciência, S.A. Conjugados de boro multifuncionais com uma estrutura tripodal, composições farmacêuticas e processos de preparação dos mesmos
NZ797702A (en) * 2017-03-13 2026-03-27 Lundbeck La Jolla Research Center Inc Dual magl and faah inhibitors
CN111971070A (zh) * 2017-12-14 2020-11-20 塔弗达治疗有限公司 Hsp90-靶向缀合物及其制剂
SMT202400369T1 (it) * 2018-09-13 2024-11-15 Celgene Corp (r)-5-carbamoilpiridin-3-il-2-metil-4-(3-(trifluorometossi)benzil)piperazin-1-carbossilato cristallino, sue composizioni e relativi metodi di utilizzo
TWI705813B (zh) 2019-05-24 2020-10-01 國立交通大學 含有ganetespib的粒子與含有該粒子的藥學組成物及其在抗癌治療上的用途
KR102322956B1 (ko) * 2020-01-07 2021-11-09 이화여자대학교 산학협력단 신규 보르테조밉 전구약물 및 이의 용도
US20230321250A1 (en) * 2020-07-08 2023-10-12 Octagon Therapeutics, Inc. Cancer cell modulators
US20240181073A1 (en) 2021-03-03 2024-06-06 Sorrento Therapeutics, Inc. Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
EP4489790A1 (en) 2022-03-10 2025-01-15 Vivasor, Inc. Antibody-drug conjugates and uses thereof
EP4687997A2 (en) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687996A1 (en) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
EP4687995A1 (en) 2023-04-05 2026-02-11 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
ES2347027T3 (es) 1998-05-22 2010-10-22 The Board Of Trustees Of The Leland Stanford Junior University Moleculas bifuncionales y terapias basadas en las mismas.
US8617514B2 (en) 1999-02-22 2013-12-31 Georgetown University Tumor-targeted nanodelivery systems to improve early MRI detection of cancer
WO2000061578A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
CA2426762A1 (en) 2000-11-02 2002-05-10 Sloan-Kettering Institute For Cancer Research Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
US7671010B2 (en) 2002-08-30 2010-03-02 The Board Of Regents Of The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
GB0211578D0 (en) 2002-05-21 2002-06-26 Univ Belfast Medicaments
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
AU2003303058A1 (en) 2002-12-12 2004-07-09 Conforma Therapeutics Corporation Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
US20070297980A1 (en) 2004-03-26 2007-12-27 Qian Xie Geldanamycin and Derivatives Inhibit Cancer Invasion and Identify Novel Targets
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2007053792A2 (en) 2005-11-05 2007-05-10 Amplyx Pharmaceuticals, Inc. Improving the pharmacokinetics of protease inhibitors and other drugs
CA2632903C (en) 2005-12-02 2015-11-24 Vianova Labs, Inc. Treatment of cancer and other diseases
GB0526615D0 (en) 2005-12-30 2006-02-08 Novartis Ag Organic compounds
US10336757B2 (en) 2006-06-30 2019-07-02 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibition of HSP90
EP2073802A1 (en) 2006-10-12 2009-07-01 Astex Therapeutics Limited Pharmaceutical combinations
TW200901960A (en) * 2007-03-05 2009-01-16 Kyowa Hakko Kogyo Kk Pharmaceutical composition
US20120003160A1 (en) 2007-06-29 2012-01-05 Amag Pharmaceuticals, Inc. Macrophage-Enhanced MRI (MEMRI) in a Single Imaging Session
EP2180880A2 (en) * 2007-07-09 2010-05-05 Glen S. Kwon Micelle encapsulation of therapeutic agents
US8466140B2 (en) 2007-09-10 2013-06-18 University Of Massachusetts Mitochondria-targeted anti-tumor agents
US20110270151A1 (en) 2008-09-08 2011-11-03 The Methodist Hospital Research Institute Image-guided energy deposition for targeted drug delivery
WO2011116181A1 (en) 2010-03-17 2011-09-22 Caris Life Sciences, Inc. Theranostic and diagnostic methods using sparc and hsp90
AU2009293140A1 (en) 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
US20110217241A1 (en) 2008-11-14 2011-09-08 University Of Maryland, Baltimore Conjugates of 19f mr imaging tracers for use in multi-chromic mri imaging
ES2534085T3 (es) 2009-08-17 2015-04-17 Roche Glycart Ag Inmunoconjugados dirigidos
WO2011133879A2 (en) 2010-04-22 2011-10-27 University Of Massachusetts Combination therapies with mitochondrial-targeted anti-tumor agents
US20120064107A1 (en) * 2010-05-18 2012-03-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other disease
US20120213854A1 (en) * 2010-09-30 2012-08-23 Fetzer Oliver S Methods of treating a subject and related particles, polymers and compositions
US20140031302A1 (en) 2010-10-22 2014-01-30 Universite De Strasbourg Pochoxime conjugates useful for the treatment of hsp90 related pathologies
EP2663305A1 (en) * 2011-01-11 2013-11-20 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with proteasome inhibitors
CA2855368A1 (en) * 2011-11-11 2013-05-16 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP2838653A4 (en) * 2012-04-18 2015-11-25 Cerulean Pharma Inc Methods and systems for polymer precipitation and generation of particles
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
EP3035938B1 (en) 2013-09-10 2020-08-19 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
EA032231B1 (ru) 2013-10-11 2019-04-30 Мерсана Терапьютикс, Инк. Конъюгаты белок-полимер-лекарственное средство
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
JP6727127B2 (ja) 2013-12-20 2020-07-29 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｐｉ３ｋ／ａｋｔシグナル経路阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置

Similar Documents

Publication Publication Date Title
JP2017505777A5 (https=)
IL262988A (en) Intentional healing
JP2017507150A5 (https=)
EP3949969A3 (en) Benzazepine compounds, conjugates, and uses thereof
WO2008083174A3 (en) Compositions and methods for the treatment of infections and tumors
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
WO2009110940A3 (en) Virus-, bacteria-, and fungi-interacting layered phyllosilicates and methods of use
WO2015151079A3 (en) Auristatin analogues and their conjugates with cell-binding molecules
WO2015097621A3 (en) Pharmaceutical combinations
CA2813849C (en) Secukinumab for use in the treatment of ankylosing spondylitis
EA201390642A1 (ru) Цитотоксические агенты, содержащие новые производные анзамитоцина
MX2010005385A (es) Medicamentos topicos para la terapia antimicotica.
WO2015134464A3 (en) Targeted therapeutics
JP2009256388A5 (https=)
WO2007112193A3 (en) Camptothecin-binding moiety conjugates
GB0710121D0 (en) Antifungal agents
CL2008000254A1 (es) Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer.
JP2016539156A5 (https=)
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
EP4424323A3 (en) Anti-folr1 immunoconjugate dosing regimens
HK1258571A1 (zh) 包含生物活性剂的聚合物缀合物
JP2016515550A5 (https=)
WO2012021800A3 (en) Caspase inhibitors as therapeutics for neural and organ injury and imaging
WO2012159027A3 (en) Osw-1 analogs and conjugates, and uses thereof
WO2015109017A3 (en) Deuterated no-releasing nonoate(oxygen-bound)chromene conjugates